Traditionally, RP for high-risk prostate cancer has been discouraged because of concerns regarding the side effects such as high rates of positive surgical margins, risk of lymph node metastasis, and high rates of PSA recurrence. The gene discussed is KLK3; the disease is prostate cancer.